7 hasil untuk "Raffaele Piscitelli"
Menampilkan 1–7 · 0,52 detik · RSS
-
Artikel Jurnal Teks lengkap
Genetic Programming-Based Feature Construction for System Setting Recognition and Component-Level Prognostics
Extracting representative feature sets from raw signals is crucial in Prognostics and Health Management (PHM) for components’ behavior understanding. The literature proposes various methods, including signal processing in the time, frequency, and time–frequency domains, feature selection, and…
-
Artikel Jurnal Teks lengkap
The inpatient hospital burden of comorbidities in HCV-infected patients: A population-based study in two Italian regions with high HCV endemicity (The BaCH study)
Background & aims: Hepatitis C (HCV) is associated with several extrahepatic manifestations, and estimates of the hospitalization burden related to these comorbidities are still limited. The aim of this study is to quantify the hospitalization risk associated with comorbidities in an Italian cohort…
Juga tersedia di: DOAJ
-
Artikel Jurnal
Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
BackgroundThe introduction of immune checkpoint inhibitors (ICIs) in clinical practice has brought significant benefits for patients. Seven ICIs are available in Europe: nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab, and ipilimumab. Despite their proven clinical efficacy…
-
Artikel Jurnal Teks lengkap
Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
Background: The introduction of trastuzumab biosimilars in clinical practice plays an important role in promoting the sustainability of healthcare systems. By contrast, the switching process can be challenging to the clinics. This survey describes the switching process at a National Cancer…
-
Artikel Jurnal
Pazopanib in metastatic renal cancer: a “real-world” experience at National Cancer Institute “Fondazione G. Pascale”
Pazopanib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma. The present study analyzed the outcomes of pazopanib in first-line treatment of mRCC, in a single Italian cancer center. In the light of the…
-
Artikel Jurnal
Axitinib after Sunitinib in metastatic renal cancer: preliminary results from Italian “Real-Word” SAX study
Axitinib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) after failure of prior treatment with Sunitinib or cytokine. The present study is an Italian Multi-Institutional Retrospective Analysis that evaluated the outcomes of Axitinib, in…